The Interleukin-6 Receptor As a Target for Prevention of Coronary Heart Disease: a Mendelian Randomisation Analysis

Background: A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.

Methods: Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis.

Findings: In 40 studies including up to 133,449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration (increase per allele 9·45%, 95% CI 8·34-10·57) as well as reduced C-reactive protein (decrease per allele 8·35%, 95% CI 7·31-9·38) and fibrinogen concentrations (decrease per allele 0·85%, 95% CI 0·60-1·10). This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials. In 25,458 coronary heart disease cases and 100,740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0·95, 95% CI 0·93-0·97, p=1·53×10(-5)).

Interpretation: On the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in populations could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses.

Funding: UK Medical Research Council; British Heart Foundation; Rosetrees Trust; US National Heart, Lung, and Blood Institute; Du Pont Pharma; Chest, Heart and Stroke Scotland; Wellcome Trust; Coronary Thrombosis Trust; Northwick Park Institute for Medical Research; UCLH/UCL Comprehensive Medical Research Centre; US National Institute on Aging; Academy of Finland; Netherlands Organisation for Health Research and Development; SANCO; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Agentschap NL; European Commission; Swedish Heart-Lung Foundation; Swedish Research Council; Strategic Cardiovascular Programme of the Karolinska Institutet; Stockholm County Council; US National Institute of Neurological Disorders and Stroke; MedStar Health Research Institute; GlaxoSmithKline; Dutch Kidney Foundation; US National Institutes of Health; Netherlands Interuniversity Cardiology Institute of the Netherlands; Diabetes UK; European Union Seventh Framework Programme; National Institute for Healthy Ageing; Cancer Research UK; MacArthur Foundation.

Citing Articles

Inflammatory Biomarkers in Coronary Artery Disease: Insights From Mendelian Randomization and Transcriptomics.

Xiao Z, Cheng X, Bai Y J Inflamm Res. 2025; 18:3177-3200.

PMID: 40059946 PMC: 11890003. DOI: 10.2147/JIR.S507274.

Anti-inflammatory Therapies for Ischemic Heart Disease.

Muhs T, Ljubojevic-Holzer S, Sattler S Curr Cardiol Rep. 2025; 27(1):57.

PMID: 39969632 PMC: 11839821. DOI: 10.1007/s11886-025-02211-0.

The 14-year cumulative genetic high blood pressure and risk of type 2 diabetes in Korean: observational and Mendelian randomization evidence.

Jeon J, Jung K, Kimm H, Lee J, Nam C, Jee S Hypertens Res. 2025; .

PMID: 39939824 DOI: 10.1038/s41440-025-02099-x.

Inflammation, Lp(a) and cardiovascular mortality: results from the LURIC study.

Wissel S, Scharnagl H, Kleber M, Delgado G, Moissl A, Kramer B Clin Res Cardiol. 2025; .

PMID: 39912915 DOI: 10.1007/s00392-025-02609-4.

Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection.

Lokau J, Garbers Y, Vicente M, Dittrich A, Meltendorf S, Lingel H Front Immunol. 2025; 15():1488745.

PMID: 39835136 PMC: 11743636. DOI: 10.3389/fimmu.2024.1488745.

References

Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T . Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011; 342:d548. PMC: 3039696. DOI: 10.1136/bmj.d548. View

Singh J, Beg S, Lopez-Olivo M . Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010; (7):CD008331. DOI: 10.1002/14651858.CD008331.pub2. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Chalaris A, Gewiese J, Paliga K, Fleig L, Schneede A, Krieger K . ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta. 2009; 1803(2):234-45. DOI: 10.1016/j.bbamcr.2009.12.001. View

Kivimaki M, Lawlor D, Davey Smith G, Kumari M, Donald A, Britton A . Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One. 2008; 3(8):e3013. PMC: 2507732. DOI: 10.1371/journal.pone.0003013. View

Hindorff L, Sethupathy P, Junkins H, Ramos E, Mehta J, Collins F . Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009; 106(23):9362-7. PMC: 2687147. DOI: 10.1073/pnas.0903103106. View

Sattar N, McInnes I . Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005; 17(3):286-92. DOI: 10.1097/01.bor.0000158150.57154.f9. View

Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View

Steiner G, Urowitz M . Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum. 2008; 38(5):372-81. DOI: 10.1016/j.semarthrit.2008.01.015. View

10.

Genovese M, McKay J, Nasonov E, Mysler E, Da Silva N, Alecock E . Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic.... Arthritis Rheum. 2008; 58(10):2968-80. DOI: 10.1002/art.23940. View

11.

Kivimaki M, Lawlor D, Eklund C, Davey Smith G, Hurme M, Lehtimaki T . Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the young Finns study. Arterioscler Thromb Vasc Biol. 2007; 27(4):978-9. DOI: 10.1161/01.ATV.0000258869.48076.14. View

12.

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T . Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112(10):3959-64. DOI: 10.1182/blood-2008-05-155846. View

13.

Mullberg J, Oberthur W, Lottspeich F, MEHL E, Dittrich E, Graeve L . The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol. 1994; 152(10):4958-68. View

14.

Kremer J, Blanco R, Brzosko M, Burgos-Vargas R, Halland A, Vernon E . Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of.... Arthritis Rheum. 2011; 63(3):609-21. DOI: 10.1002/art.30158. View

15.

Rafiq S, Frayling T, Murray A, Hurst A, Stevens K, Weedon M . A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun. 2007; 8(7):552-9. PMC: 2668154. DOI: 10.1038/sj.gene.6364414. View

16.

Jones S, Horiuchi S, Topley N, Yamamoto N, Fuller G . The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001; 15(1):43-58. DOI: 10.1096/fj.99-1003rev. View

17.

Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M . Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5(12):1731-40. DOI: 10.1016/j.intimp.2005.05.010. View

18.

Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G . The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993; 23(2):473-80. DOI: 10.1002/eji.1830230226. View

19.

Smolen J, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E . Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617):987-97. DOI: 10.1016/S0140-6736(08)60453-5. View

20.

Casas J, Shah T, Cooper J, Hawe E, McMahon A, Gaffney D . Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol. 2006; 35(4):922-31. DOI: 10.1093/ije/dyl041. View